Press Releases

• Alto Neuroscience: Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome From Recent FDA Meeting More
• Atropos Health: Launches the Atropos Evidence Agent at Stanford Health Care and Collaborates With Microsoft to Improve Evidence-Based Personalized Medicine at the Point of Care More
• BeOne Medicines: Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025 More
• Biogenesis: Emerges From Stealth to Accelerate Clinical Trials for Pharmaceutical Industry More
• CatalYm: Presents Long-Term Phase 1/2a Data Confirming Sustained Responses With Visugromab in CPI-Refractory Tumors at ESMO 2025 More
• Charles River: Charles River and X-Chem Announce Strategic Collaboration to Enhance Hit Identification Capabilities More
• Corvus Pharmaceuticals: Presentation of Interim Data From the Phase 1b/2 Clinical Trial of Ciforadenant for Patients With Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025 More
• Exelixis: Detailed Results From Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination With an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet More More*
• Exelixis: Results From Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 More
• Genentech: FDA Approves Gazyva for the Treatment of Lupus Nephritis More More More*
• Genentech: Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment More
• IDEAYA Biosciences: Positive Median Overall Survival Data From Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress More
  
• IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025 More More*
• IMVARIA: AI-Powered, Non-Invasive Bronchosolve Solution Meets Primary Endpoints for Lung Cancer Diagnosis in Pivotal VIRTUAL-BRONCH Study More
• Nurix Therapeutics: Reports New Clinical Data From First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress More
• RAPT Therapeutics and Shanghai Jeyou Pharmaceutical: Positive Topline Data From Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria More
• Silver Creek Pharmaceuticals: Receives FDA Fast Track Designation for Scp776 in Acute Ischemic Stroke More
• Valitor: Appoints Biotech and Ophthalmic Industry Veteran Gregory D. Kunst as Chief Executive Officer More
• Valitor: Presents Preclinical Data Demonstrating VLTR-559 Achieves Superior Durability and Sustained Anti-VEGF Activity With a Favorable Safety Profile as a Treatment for Wet AMD More

Financial News

• Adaptyx: Raises $14M in Seed Financing to Launch Wearable Platform for Continuous Multi-Analyte Molecular Monitoring More
• Alto Neuroscience: $50 Million Private Placement Financing More
• Cancer Early-detection Test Company Grail Raises $325 Million More* More
  
• Exclusive VC Funding Data from BYTE51, with Special Big4Bio Pricing More
• 4DMT Announces New Employment Inducement Grants More
• Iovance Biotherapeutics: Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) More
• XOMA Royalty and LAVA Therapeutics: Amendment to Purchase Agreement More More 

Media/Misc Coverage

• Subscribe to LifeSci Startup for Updates on US Startups More

Companies

Career Center

• Elevating Executive Presence: A Blueprint for Life Sciences and Biotech Leaders More
• CEO’s Perspective: Big Moves Come with Big Responsibility More
• CEO’s Perspective: The High Cost of Job Hopping More
• ICYMI: The Power of Peer Learning - Why Even Top Biotech Leaders Need Mentorship More
• Shape’s Former CSO Picks Up Tech Role at Moderna; Lilly Reels In Peter Marks More*
• What’s Next in Precision Medicine: Leadership Challenges and Opportunities More

• Biocom California CEO Summit (Bay Area/Wine Country) Oct 24
• 15th Annual PODD Conference Oct 27-28
• New Jersey Life Sciences & Biotech Conference Oct 28
• Biocom California CEO Summit (Los Angeles) Oct 29
• Pantheon 2025 Nov 6
• BIO-Europe 2025 Nov 11-12
• Copay, Reimbursement and Access Congress (Save 10% with VIP code: 25B4B10) Nov 18-20
• Pharma/Biotech Gross-To-Net Summit (Save 10% with VIP code: 25B4B10) Nov 18-20
• Patient Support Services Congress (Save 10% with VIP code: 25B4B10) Nov 20-21
• Compounding Pharmacy Compliance (Save 10% with VIP code: 25B4B10) Dec 9-10
• Trade and Channel Strategies (Save 10% with VIP code: 25B4B10) Dec 9-11
  
• Advancing Drug Development Forum Dec 11

SF Bay Sponsors